Second quarter and first half 2020 financial report

21. Aug 2020 | 2 min read

Moss, 21 August 2020

Gentian Diagnostics AS announces its results for the second quarter and first half of 2020. The highlights include:

  • Record sales revenues of MNOK 16.6 in 2Q20, up from MNOK 10.2 in 2Q19
  • Sales growth in 2Q20 of 64 % is especially based on Cystatin C sales in Asia. Sales in the quarter grew by 44 % YoY on a currency neutral basis
  • Successful release of fPELA® turbo, which is marketed by our partner BÜHLMANN
  • Gentian awarded up to MNOK 8.0 in funding to support the development of a high-throughput SARS-CoV-2 antibody test
  • New scientific publications propose calprotectin as a promising biomarker for the management of COVID-19 patients, which represents a new opportunity for our GCAL® assay

Please find the report and results presentation here:

GDAS Interim Report 2Q 2020

GDAS Interim Presentation 2Q 2020

 

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

MeldingsID: 511876
UtstederID: GENT-ME
Marked: Merkur Market

You may also read


Nov 20, 2020 - Kristin Hart

New study results confirm the value of calprotectin in management of COVID-19 patients

Moss, Norway 20.11.2020 Gentian Diagnostics AS is pleased to announce that the results from a study conducted..

Nov 05, 2020 - Julie

Gentian Diagnostics divests its subsidiary PreTect AS

Gentian Diagnostics today announces the divestiture of its subsidiary PreTect AS to Mel-Mont Medical, Inc...